Study Number: I11054B
Test Type: TOX
Route: Dosing in Water
Species/Strain: Rat/Harlan Sprague Dawley

M19: TDAR SRBC: ELISpot
Test Compound: Sulfolane
CAS Number: 126-33-0

Date Report Requested: 12/07/2018
Time Report Requested: 07:31:59
Lab: Burleson Research Technologies

C Number: I11054B
Study Gender: Both
PWG Approval Date: See web page for date of PWG Approval
**F1 Males**

<table>
<thead>
<tr>
<th>Treatment Groups (mg/L)</th>
<th>0</th>
<th>30</th>
<th>100</th>
<th>300</th>
<th>1000</th>
<th>15 mg/kg CPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM AFC/10^5 Spleen Cells</td>
<td>184.6 ± 49.1 (12)</td>
<td>216.3 ± 69.3 (12)</td>
<td>198.8 ± 47.8 (12)</td>
<td>195.8 ± 52.5 (12)</td>
<td>215.8 ± 34.9 (12)</td>
<td>27.5 ± 3.1 (8)</td>
</tr>
<tr>
<td>IgM AFC/Spleen (x10^3)</td>
<td>67.22 ± 16.66 (12)</td>
<td>82.85 ± 28.34 (12)</td>
<td>76.33 ± 20.85 (12)</td>
<td>80.80 ± 22.81 (12)</td>
<td>85.98 ± 13.80 (12)</td>
<td>3.24 ± 0.48 (8) **</td>
</tr>
</tbody>
</table>
### F1 Females

<table>
<thead>
<tr>
<th>Treatment Groups (mg/L)</th>
<th>0</th>
<th>30</th>
<th>100</th>
<th>300</th>
<th>1000</th>
<th>15 mg/kg CPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>IgM AFC/10^6 Spleen Cells</td>
<td>230.4 ± 30.6 (12)</td>
<td>301.7 ± 47.8 (12)</td>
<td>357.3 ± 107.8 (12)</td>
<td>379.0 ± 91.2 (12)</td>
<td>278.3 ± 40.3 (12)</td>
<td>21.3 ± 4.9 (8) **</td>
</tr>
<tr>
<td>IgM AFC/Spleen (x10^3)</td>
<td>76.42 ± 11.23 (12)</td>
<td>104.58 ± 17.97 (12)</td>
<td>127.19 ± 35.75 (12)</td>
<td>152.24 ± 26.44 (12) *</td>
<td>105.19 ± 14.13 (12)</td>
<td>2.51 ± 0.55 (8) **</td>
</tr>
</tbody>
</table>
LEGEND

Data are displayed as mean ± SEM (N) unless otherwise noted.
TDAR - T-Dependent Antibody Response; SRBC - Sheep Red Blood Cells; AFC - Antibody-Forming Cells; IgM - Immunoglobulin M
Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests (unless otherwise noted).
Statistical analysis for the positive control group compared to the vehicle control group was performed using the Kruskal-Wallis test.
* Statistically significant at P <= 0.05
** Statistically significant at P <= 0.01
Statistical significance for the control group indicates a significant trend test
Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group
CPS = Cyclophosphamide

** END OF REPORT **